Why this matters

If you have shopped for a compounded weight-loss drug online, you have almost certainly read the kind of marketing the FDA just went after. During the week of June 15, 2026, the agency issued 25 warning letters to telehealth companies, saying their websites made false or misleading claims about compounded versions of semaglutide and tirzepatide — the active ingredients in the brand-name GLP-1 drugs Wegovy, Ozempic, Zepbound, and Mounjaro. The agency posted the letters publicly and, alongside them, launched two new reference pages spelling out exactly which claims it considers a problem.

For a reader buying compounded GLP-1s through a telehealth platform, this is less a news event than a reading guide. The letters are essentially a list of the sentences a sales page is not supposed to say.

What the letters target

The FDA frames these as misbranding violations under the Federal Food, Drug, and Cosmetic Act, Sections 502(a) and 502(n). The core idea is "net impression": even technically accurate sentences can be misleading if the page as a whole leaves a shopper believing a compounded product is FDA-approved or equivalent to an approved drug. According to the agency's own summary and the warning letters, the recurring problems include:

  • Calling a compounded product a "generic" version of an approved GLP-1 drug. Compounded drugs are not FDA-approved generics.
  • Implying the FDA approved, reviewed, or evaluated the product for safety or effectiveness.
  • "Clinically proven" or "same results" language that implies the compounded version performs like the approved drug.
  • Saying a product is sourced from an "FDA-approved" or "FDA-licensed" pharmacy — the FDA does not approve or license compounding pharmacies in that way.
  • Branding or labeling that makes the telehealth company look like the actual compounder when it is not.
  • "Exact same active ingredient" phrasing used to imply the compounded product is the same as the brand.
What "compounded" actually means

A compounded drug is custom-made by a pharmacy. It can be legal and legitimately useful — for shortages or specific patient needs — but it does not go through the FDA review for safety, effectiveness, and manufacturing quality that approved drugs do. "Not FDA-approved" is a description of the regulatory pathway, not an automatic verdict on any one product.

The pattern behind the numbers

This is the third large batch of letters in under a year, part of a broader push against direct-to-consumer drug advertising:

Sept 2025Roughly 80 warning letters and 40 untitled letters across compounded GLP-1s and other compounded drugs.
March 202630 warning letters to telehealth firms.
June 202625 warning letters, plus two new FDA reference webpages.

CDER Acting Director Michael Davis reinforced the message publicly, writing on X that "compounded GLP-1 products have not been proven safe, effective, or of consistent quality like FDA-approved drugs." Separately, the FDA's compounded-GLP-1 page notes that as of May 21, 2026, it had received more than 1,700 adverse-event reports tied to compounded semaglutide and tirzepatide.

What this does and doesn't say

Warning letters are allegations, not court rulings or proof of harm — they assert that specific marketing language is misleading and ask companies to fix it. They are about claims, not a finding that any particular vial is contaminated or dangerous. Equally, the action does not mean compounded GLP-1s are illegal or that everyone using one is at risk. What it does establish is that the FDA considers a large share of how these products are sold online to be misleading, and that it is watching in coordinated waves rather than steadily — so a quiet stretch is not a sign the scrutiny has eased.

Why it matters for this audience

Compounded GLP-1s reach a lot of women in midlife through telehealth, often at a fraction of brand-name prices. That price gap is real, but it comes with a quieter trade-off: less of the manufacturing oversight that approved drugs carry. The practical takeaway from these letters is a short test for any sales page. If it calls the product "generic," "FDA-approved," "clinically proven," or "the same as" the brand — or makes the seller look like the lab that made it — those are precisely the phrases the FDA just flagged. None of that tells you a specific product is unsafe, but it tells you the marketing is not a reliable source of truth, and that questions about the actual compounding pharmacy belong with your prescriber.

What's next

The agencies involved have signaled this is an ongoing priority, so more batches are likely. The two new FDA webpages — one for telehealth companies on promoting compounded drugs, one on its broader concerns with compounded GLP-1s — are the clearest plain-record of what the agency expects, and worth a look before any compounded-GLP-1 purchase.

All content on Peptide Price Lab is for informational and research purposes only. Nothing here constitutes medical advice. Always consult a licensed healthcare provider before making any health or treatment decisions. Regulatory status can change; this reflects publicly available information as of June 2026.

Sources

  1. 1. U.S. Food and Drug Administration. "FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs." FDA.gov, 2026.
  2. 2. U.S. Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." FDA.gov, 2026.
  3. 3. DiSabatino, D. & Klein, J. (Sheppard Mullin). "FDA's Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters." The National Law Review, June 18, 2026.
  4. 4. Reuters. "US FDA sends 25 letters to telehealth companies over claims on compounded weight-loss drugs." June 16, 2026.